mycosis fungoides

Summary

Summary: A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.

Top Publications

  1. Schwingshackl P, Obermoser G, Nguyen V, Fritsch P, Sepp N, Romani N. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Acta Derm Venereol. 2012;92:269-75 pubmed publisher
    ..b>Mycosis fungoides and Sézary syndrome (n = 25) were investigated immunohistochemically for DC subsets, based on C-type lectin ..
  2. Kim Y, Gratzinger D, Harrison C, Brody J, Czerwinski D, Ai W, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012;119:355-63 pubmed publisher
    ..We have now explored this strategy in a second disease: mycosis fungoides (MF). We treated 15 patients...
  3. Jones G, Wilson L, Fox Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am. 2003;17:1421-34 pubmed
    ..Meanwhile, adjuvant PUVA and ECP may significantly improve results, but further data are needed to confirm these preliminary findings (see references [23, 34, 39, 40, 42])...
  4. Kim S, Sim H, Jeon Y, Lee J, Roh H, Choi S, et al. Clinicopathological features and T-cell receptor gene rearrangement findings of mycosis fungoides in patients younger than age 20 years. J Dermatol. 2009;36:392-402 pubmed publisher
    b>Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma that usually arises in middle-aged or older people. The incidence of childhood MF is low, but studies in childhood MF suggests that the incidence is rising...
  5. Wong H, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155:150-66 pubmed publisher
    ..The most common forms of CTCL are Mycosis Fungoides (MF) and Sezary Syndrome (SS)...
  6. LEE C, Ungewickell A, Bhaduri A, Qu K, Webster D, Armstrong R, et al. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood. 2012;120:3288-97 pubmed publisher
    ..Our findings characterize the SS transcriptome and support recent reports that implicate lncRNA dysregulation in human malignancies...
  7. Gerami P, Rosen S, Kuzel T, Boone S, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144:738-46 pubmed publisher
    To study the clinical features, therapeutic responses, and outcomes in patients with folliculotropic mycosis fungoides (FMF) and to compare our single-center experience of 43 patients with the findings from the Dutch Cutaneous Lymphoma ..
  8. Kreuter A, Bischoff S, Skrygan M, Wieland U, Brockmeyer N, Stucker M, et al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides. Arch Dermatol. 2008;144:1011-6 pubmed publisher
    ..of human herpesvirus 8 (HHV-8) in lesional skin of German patients with large-plaque parapsoriasis (LPP) or mycosis fungoides (MF). The pathogenetic relevance of HHV-8 in cutaneous T-cell lymphoma is controversial...
  9. van Doorn R, van Kester M, Dijkman R, Vermeer M, Mulder A, Szuhai K, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113:127-36 pubmed publisher
    b>Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is a malignancy of mature, skin-homing T cells. Sézary syndrome (Sz) is often considered to represent a leukemic phase of MF...

More Information

Publications76

  1. Olsen E, Whittaker S, Kim Y, Duvic M, Prince H, Lessin S, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of . J Clin Oncol. 2011;29:2598-607 pubmed publisher
    b>Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas...
  2. Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao C, et al. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol. 2012;132:1698-706 pubmed publisher
    The lack of a specific marker differentiating early mycosis fungoides (eMF) from benign inflammatory dermatitis presents significant difficulties in the assessment and management of suspected MF patients, which often leads to delayed ..
  3. Kopp K, Kauczok C, Lauenborg B, Krejsgaard T, Eriksen K, Zhang Q, et al. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia. 2010;24:1179-85 pubmed publisher
    ..T-cell lymphoma (CTCL) as well as in situ in lymphocytic cells in 21 out of 22 patients suffering from mycosis fungoides (MF) in plaque or tumor stage...
  4. Abbott R, Sahni D, Robson A, Agar N, Whittaker S, Scarisbrick J. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. J Am Acad Dermatol. 2011;65:313-319 pubmed publisher
    Poikilodermatous mycosis fungoides (MF) is a variant of MF, and its clinicopathological, immunophenotypic, molecular, and prognostic features have not previously been defined in the literature...
  5. Querfeld C, Rosen S, Guitart J, Rademaker A, Pezen D, Dolan M, et al. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O?-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res. 2011;17:5748-54 pubmed publisher
    ..Malignant CD4(+) T cells of patients with mycosis fungoides/Sézary syndrome (MF/SS) have been shown to have low levels of MGMT and may be particularly sensitive to ..
  6. Fukushima T, Horio K, Matsuo E, Imanishi D, Yamasaki R, Tsushima H, et al. Successful cord blood transplantation for mycosis fungoides. Int J Hematol. 2008;88:596-598 pubmed publisher
    A 26-year-old female diagnosed as mycosis fungoides (MF, clinical stage IV) was treated with single-agent chemotherapy, multi-drug chemotherapy and unrelated bone marrow transplantation with reduced-intensity conditioning (engraftment ..
  7. Hegyi J, Frey T, Arenberger P. Unilesional mycosis fungoides treated with photodynamic therapy. A case report. Acta Dermatovenerol Alp Pannonica Adriat. 2008;17:75-8 pubmed
    b>Mycosis fungoides, or cutaneous T-cell lymphoma (CTCL), is one of the most common skin lymphomas, with a chronic and lethal course...
  8. Abbott R, Whittaker S, Morris S, Russell Jones R, Hung T, Bashir S, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160:1299-307 pubmed publisher
    ..Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL)...
  9. Belousova I, Vanecek T, Samtsov A, Michal M, Kazakov D. A patient with clinicopathologic features of small plaque parapsoriasis presenting later with plaque-stage mycosis fungoides: report of a case and comparative retrospective study of 27 cases of "nonprogressive" small plaque parapsoriasis. J Am Acad Dermatol. 2008;59:474-82 pubmed publisher
    ..small plaque parapsoriasis (SPP) represents an inflammatory dermatosis or has a potential to transform into mycosis fungoides (MF) or is, in fact, MF. The literature contains no fully documented example of progression of SPP into MF.
  10. Khopkar U, Doshi B, Dongre A, Gujral S. A study of clinicopathologic profile of 15 cases of hypopigmented mycosis fungoides. Indian J Dermatol Venereol Leprol. 2011;77:167-73 pubmed publisher
    b>Mycosis fungoides (MF) is cutaneous lymphoma of the T-cell lineage. Hypopigmented MF is a clinical variant of MF, described mainly in Asians. This is a retrospective clinicopathologic analysis of hypopigmented MF at a tertiary care center.
  11. Lee J, Viakhireva N, Cesca C, Lee P, Kohler S, Hoppe R, et al. Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. J Am Acad Dermatol. 2008;59:706-12 pubmed publisher
    Woringer-Kolopp disease, also known as pagetoid reticulosis, is an exceedingly rare variant of mycosis fungoides. Accurate diagnosis and effective treatment is essential to prevent progression to debilitating disease...
  12. Ballabio E, Mitchell T, van Kester M, Taylor S, Dunlop H, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116:1105-13 pubmed publisher
    ..Levels of miR-223 distinguished SzS samples (n = 32) from healthy controls (n = 19) and patients with mycosis fungoides (n = 11) in more than 90% of samples...
  13. Yamashita T, Abbade L, Marques M, Marques S. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. An Bras Dermatol. 2012;87:817-28; quiz 829-30 pubmed
    This paper reviews the diagnostic and classificatory concepts of mycosis fungoides and Sézary syndrome in light of the latest normative publications...
  14. Ponte P, Serrao V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2010;24:716-21 pubmed publisher
    b>Mycosis fungoides (MF) is a non-Hodgkin's T-cell lymphoma of the skin that often begins as limited patches and plaques with slow progression to systemic involvement...
  15. Edinger J, Clark B, Pucevich B, Geskin L, Swerdlow S. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33:1860-8 pubmed publisher
    ..cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, pagetoid reticulosis and transformed mycosis fungoides (MF)...
  16. Salgado R, Servitje O, Gallardo F, Vermeer M, Ortiz Romero P, Karpova M, et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol. 2010;130:1126-35 pubmed publisher
    ..3 (CDKN2A, CDKN2B, and MTAP) and 10q26qter (MGMT and EBF3) may have an important role in prognosis. In addition, we describe the MFt genomic instability profile, which, to our knowledge, has not been reported earlier...
  17. Martínez González M, Verea Hernando M, Yebra Pimentel M, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol. 2008;18:148-52 pubmed publisher
    ..We assayed topical imiquimod in treating early stages of mycosis fungoides. We applied imiquimod 5% cream in four patients with multi-treatment resistant plaques of MF (stages IA and ..
  18. van Kester M, Ballabio E, Benner M, Chen X, Saunders N, van der Fits L, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol. 2011;5:273-80 pubmed publisher
    ..In this study we determined the complete miRNome of mycosis fungoides (MF), the most common type of cutaneous T cell lymphoma...
  19. Alsaleh Q, Nanda A, Al Ajmi H, Al Sabah H, Elkashlan M, Al Shemmari S, et al. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol. 2010;49:1393-8 pubmed
    b>Mycosis fungoides (MF) is an indolent, most common type of cutaneous T-cell lymphoma (CTCL) with an average estimated incidence of 0.5 cases per 100,000 persons per year in the western world...
  20. Agar N, Wedgeworth E, Crichton S, Mitchell T, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-9 pubmed publisher
    We have analyzed the outcome of mycosis fungoides (MF) and Sézary syndrome (SS) patients using the recent International Society for Cutaneous Lymphomas (ISCL)/European Organisation for Research and Treatment of Cancer (EORTC) revised ..
  21. Furmanczyk P, Wolgamot G, Kussick S, Sabath D, Olerud J, Argenyi Z. Diagnosis of mycosis fungoides with different algorithmic approaches. J Cutan Pathol. 2010;37:8-14 pubmed publisher
    Algorithmic scoring approaches for evaluating early cases of mycosis fungoides (MF) provide a degree of diagnostic standardization...
  22. Horwitz S, Olsen E, Duvic M, Porcu P, Kim Y. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6:436-42 pubmed
    ..Guidelines in Oncology: Non-Hodgkin's Disease were recently revised to include recommendations for treating mycosis fungoides and Sézary syndrome...
  23. Wu P, Kim Y, Lavori P, Hoppe R, Stockerl Goldstein K. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009;15:982-90 pubmed publisher
    The survival outlook in advanced mycosis fungoides (MF) is poor...
  24. Xiao T, Xia L, Yang Z, He C, Gao X, Chen H. Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides. Eur J Dermatol. 2008;18:660-2 pubmed publisher
    Recently there have been some reports concerned the treatment of early stage mycosis fungoides (MF) with narrow-band ultraviolet B (NB-UVB) phototherapy...
  25. Smoller B. Mycosis fungoides: what do/do not we know?. J Cutan Pathol. 2008;35 Suppl 2:35-9 pubmed publisher
    b>Mycosis fungoides is one type of T cell lymphoma characterized by a constellation of clinical, histologic, immunologic and molecular findings...
  26. Cho Vega J, Tschen J, Duvic M, Vega F. Early-stage mycosis fungoides variants: case-based review. Ann Diagn Pathol. 2010;14:369-85 pubmed publisher
    b>Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. The diagnosis of classic MF is based on a combination of clinical presentation, histopathology, and T-cell monoclonality detected by molecular studies...
  27. Salehi M, Azimi Z, Fatemi F, Rajabi P, Kazemi M, Amini G. Incidence rate of mycosis fungoides in Isfahan (Iran). J Dermatol. 2010;37:703-7 pubmed publisher
    b>Mycosis fungoides (MF) is an extranodal non-Hodgkin's lymphoma with primary involvement of the skin. The aim of the present study was to determine the incidence rate of MF in Isfahan (Iran) and to compare the results with other reports...
  28. Beyer M, Möbs M, Humme D, Sterry W. Pathogenesis of Mycosis fungoides. J Dtsch Dermatol Ges. 2011;9:594-8 pubmed publisher
    b>Mycosis fungoides is the most common type of primary cutaneous lymphomas...
  29. Sarveswari K, Yesudian P. The conundrum of parapsoriasis versus patch stage of mycosis fungoides. Indian J Dermatol Venereol Leprol. 2009;75:229-35 pubmed publisher
    ..confusion with benign dermatosis, such as parapsoriasis en plaques, makes it difficult to diagnose mycosis fungoides in the early patch stage...
  30. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365-72 pubmed publisher
    Transformed mycosis fungoides (MF) and Sézary syndrome (SS) are currently incurable...
  31. Fenot M, Maillard H, Sierra Fortuny S, De Ybarlucea L, Celerier P. [Syringotropic cutaneous T-cell lymphoma mimicking dermatomycosis]. Ann Dermatol Venereol. 2012;139:50-3 pubmed publisher
    ..Cutaneous syringotropic T-cell lymphoma is a rare form of lymphoma. We report a case involving a misleading cutaneous presentation on the sole of the foot...
  32. Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol. 2012;39:500-7 pubmed publisher
    The mechanisms of tumor progression in mycosis fungoides (MF) and Sézary syndrome (SS) are poorly understood...
  33. Parker S, Bethaney J. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update. G Ital Dermatol Venereol. 2009;144:467-85 pubmed
    b>Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma (CTCL) and, for unclear reasons, its incidence appears to be increasing...
  34. Navi D, Riaz N, Levin Y, Sullivan N, Kim Y, Hoppe R. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol. 2011;147:561-7 pubmed publisher
    ..experience with total skin electron-beam therapy (TSEBT) of 30 Gy or greater as monotherapy in patients with mycosis fungoides (MF) and compare with subgroups receiving adjuvant nitrogen mustard (HN2), and further update our experience ..
  35. Chandra P, Plaza J, Zuo Z, Diwan A, Koeppen H, Duvic M, et al. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. Am J Clin Pathol. 2009;131:511-5 pubmed publisher
    Clusterin expression is common in systemic and cutaneous anaplastic large cell lymphoma (ALCL). Mycosis fungoides (MF) in large cell transformation can resemble ALCL...
  36. Ngo J, Trotter M, Haber R. Juvenile-onset hypopigmented mycosis fungoides mimicking vitiligo. J Cutan Med Surg. 2009;13:230-3 pubmed
    b>Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma and typically affects older adults. It is estimated that less than 5% of MF cases are of juvenile onset...
  37. Maj J, Jankowska Konsur A, Sadakierska Chudy A, Noga L, Reich A. Altered microRNA expression in mycosis fungoides. Br J Dermatol. 2012;166:331-6 pubmed publisher
    ..MicroRNAs are small noncoding RNA molecules involved in the regulation of various physiological and pathological processes. Altered expression of different microRNAs has been observed in both solid tumours and haematological malignancies...
  38. Pope E, Weitzman S, Ngan B, Walsh S, Morel K, Williams J, et al. Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg. 2010;14:1-6 pubmed
    There are limited data on the clinical presentation and progression of pediatric cutaneous lymphoma. This study focuses on the clinical characteristics of pediatric patients with mycosis fungoides (MF).
  39. McGirt L, Thoburn C, Hess A, Vonderheid E. Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed. 2010;26:182-91 pubmed publisher
  40. Apa D, Pfeiffer E, Baz K, Kanik E, Inandioğlu P. Histopathological changes seen in mycosis fungoides patients after phototherapy. Am J Dermatopathol. 2010;32:276-80 pubmed publisher
    Early stage (IA, IB, IIA) mycosis fungoides (MF) has long been treated with various agents including oral psoralen plus UVA (PUVA), broadband and narrowband...
  41. Nanda A, Alsaleh Q, Al Ajmi H, Al Sabah H, Elkashlan M, Al Shemmari S, et al. Mycosis fungoides in Arab children and adolescents: a report of 36 patients from Kuwait. Pediatr Dermatol. 2010;27:607-13 pubmed publisher
    b>Mycosis fungoides (MF) is rare in children and adolescents. This study was aimed to determine the clinicoepidemiologic features of juvenile onset (?18 yrs) MF in Kuwait...
  42. Dereure O, Picot E, Comte C, Bessis D, Guillot B. Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results. Dermatology. 2009;218:1-6 pubmed publisher
    Narrowband ultraviolet B (UVB) phototherapy is increasingly used in mycosis fungoides (MF).
  43. Krejsgaard T, Odum N, Geisler C, Wasik M, Woetmann A. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia. 2012;26:424-32 pubmed publisher
    ..Patients with the two predominant clinical forms of CTCL called mycosis fungoides (MF) and Sézary syndrome (SS) characteristically develop severe immunodeficiency during disease progression ..
  44. Fink Puches R, Wolf P, Kerl H, Cerroni L. Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides. Arch Dermatol. 2008;144:1169-73 pubmed publisher
    A possible association between lichen aureus (LA) and mycosis fungoides (MF) has been suggested in the past. We evaluated the clinicopathologic features of LA and its relationship to MF...
  45. Bonin S, Tothova S, Barbazza R, Brunetti D, Stanta G, Trevisan G. Evidence of multiple infectious agents in mycosis fungoides lesions. Exp Mol Pathol. 2010;89:46-50 pubmed publisher
    The etiology of mycosis fungoides (MF) remains to be determined. Several studies have proposed a viral etiology with controversial results...
  46. Talpur R, Demierre M, Geskin L, Baron E, Pugliese S, Eubank K, et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2011;11:219-27 pubmed publisher
    To demonstrate the efficacy of the UVAR XTS Photopheresis System and evaluate health-related quality of life in patients with early-stage mycosis fungoides (MF).
  47. Rasheed H, Tolba Fawzi M, Abdel Halim M, Eissa A, Mohammed Salem N, Mahfouz S. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides. Am J Dermatopathol. 2010;32:162-9 pubmed publisher
    ..was carried out to review the immunohistological staining of MMP-9 in skin lesions of different stages of mycosis fungoides (MF). The study was carried on 22 patients with MF and 10 healthy controls...
  48. McGirt L, Adams C, Baerenwald D, Zwerner J, Zic J, Eischen C. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134:1101-1107 pubmed publisher
    The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear. MicroRNA (miRNA) are small noncoding RNAs that target mRNA leading to reduced mRNA translation...
  49. Jacobsen E, Kim H, Ho V, Cutler C, Koreth J, Fisher D, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608-13 pubmed publisher
    ..The prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome...
  50. Dummer R, Quaglino P, Becker J, Hasan B, Karrasch M, Whittaker S, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30:4091-7 pubmed publisher
    b>Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. There is a need for multicenter trials involving defined patient populations using rigorous assessment criteria...
  51. Campbell J, Clark R, Watanabe R, Kupper T. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767-71 pubmed publisher
    ..leukemic variants (L-CTCL) such as Sézary syndrome (SS) and primarily cutaneous variants such as mycosis fungoides (MF)...
  52. Lin W, Girardi M. More or less: copy number alterations in mycosis fungoides. J Invest Dermatol. 2010;130:926-8 pubmed publisher
    b>Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin's lymphomas of skin-homing T cells...
  53. Green W, Leicht S, Youngberg G. Patch-stage mycosis fungoides in remission after therapy with alefacept. J Am Acad Dermatol. 2008;58:S110-2 pubmed publisher
  54. Duarte R, Canals C, Onida F, Gabriel I, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492-9 pubmed publisher
    To analyze the outcome of allogeneic transplantation for mycosis fungoides and Sézary syndrome (MF/SS) in terms of nonrelapse mortality (NRM), relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) and to ..
  55. Zhang B, Beck A, Taube J, Kohler S, Seo K, Zwerner J, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn. 2010;12:320-7 pubmed publisher
    The distinction between mycosis fungoides (MF) and inflammatory dermatoses (ID) by clinicopathologic criteria can be challenging...
  56. Friedland R, David M, Feinmesser M, Barzilai A, Hodak E. NB-UVB (311-312 nm)-induced lentigines in patients with mycosis fungoides: a new adverse effect of phototherapy. J Eur Acad Dermatol Venereol. 2012;26:1158-62 pubmed publisher
    ..Their appearance following treatment with narrow-band ultraviolet B (NB-UVB) radiation has been reported in only two patients...
  57. Prince H, Whittaker S, Hoppe R. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009;114:4337-53 pubmed publisher
    The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS)...
  58. Herro E, DiCaudo D, Davis M, Weaver A, Swanson D. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol. 2009;61:271-5 pubmed publisher
    Having either mycosis fungoides or B-cell lymphoma may predispose a patient to the other.
  59. Benner M, Jansen P, Vermeer M, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119:1643-9 pubmed publisher
    Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an aggressive clinical course and poor survival, requiring aggressive therapeutic approach...
  60. Pfaltz K, Kerl K, Palmedo G, Kutzner H, Kempf W. Clonality in sarcoidosis, granuloma annulare, and granulomatous mycosis fungoides. Am J Dermatopathol. 2011;33:659-62 pubmed publisher
    ..The analysis of T-cell clonality is a useful diagnostic adjunct in the differentiation between sarcoidosis and GA from granulomatous CTCLs...
  61. Pai R, Mullins F, Kim Y, Kong C. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. Cancer. 2008;114:323-32 pubmed publisher
    The most common presenting site of extracutaneous disease in mycosis fungoides and Sezary syndrome is the peripheral lymph node...
  62. van Kester M, Borg M, Zoutman W, Out Luiting J, Jansen P, Dreef E, et al. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol. 2012;132:2050-9 pubmed publisher
    b>Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL)...
  63. Benner M, Ballabio E, van Kester M, Saunders N, Vermeer M, Willemze R, et al. Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides. Exp Dermatol. 2012;21:632-4 pubmed publisher
    ..benign inflammatory dermatoses (BID) as previously used to study the miRNA expression profile of tumor-stage mycosis fungoides (MF). We identified 13 differentially expressed miRNAs between C-ALCL and BID...
  64. Marta G, Gouvêa C, Ferreira S, Hanna S, Haddad C, Silva J. Mycosis fungoides: case report treated with radiotherapy. An Bras Dermatol. 2011;86:561-4 pubmed
    b>Mycosis fungoides is a rare type of non-Hodgkin's lymphoma of T cells that primarily affects the skin...
  65. Pedersen I, Willerslev Olsen A, Vetter Kauczok C, Krejsgaard T, Lauenborg B, Kopp K, et al. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma. 2013;54:819-26 pubmed publisher
    Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL)...
  66. Kempf W, Ostheeren Michaelis S, Paulli M, Lucioni M, Wechsler J, Audring H, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008;144:1609-17 pubmed publisher
    ..We studied 19 patients with granulomatous CTCLs to further characterize the clinicopathological, therapeutic, and prognostic features...
  67. Rongioletti F, De Lucchi S, Meyes D, Mora M, Rebora A, Zupo S, et al. Follicular mucinosis: a clinicopathologic, histochemical, immunohistochemical and molecular study comparing the primary benign form and the mycosis fungoides-associated follicular mucinosis. J Cutan Pathol. 2010;37:15-9 pubmed publisher